Brief: Virios Therapeutics Completes Enrollment In IMC-2 Phase 2 Long-COVID Study
23/07/2024 14:21
July 23 (Reuters) - Virios Therapeutics Inc VIRI.O :
* VIRIOS THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN
IMC-2
PHASE 2 LONG-COVID STUDY BEING CONDUCTED BY BATEMAN HORNE CENTER
Source text for Eikon: ID:nGNX6CZpN0
Further company coverage: VIRI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dogwood Therapeutics
See all newsDogwood Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Dogwood Therapeutics Q2 net loss widens on higher costs, impairment charge
Brief: Dogwood Therapeutics Q2 EPS USD -0.34
Dogwood Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Dogwood Therapeutics Announces Commencement Of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2B Long Term Extension Study